

Boston Scientific Announces Appointment of Timothy Pratt as General Counsel

PRNewswire-FirstCall
NATICK, Mass., April 7
(NYSE:BSX)

NATICK, Mass., April 7, 2008 /[PRNewswire-FirstCall](#)/ -- Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Timothy Pratt as its new General Counsel. Pratt is a nationally known attorney specializing in medical device and pharmaceutical litigation. He will hold the title of "Executive Vice President, Secretary and General Counsel;" he will serve on the Company's Executive Committee, and he will report to President and Chief Executive Officer Jim Tobin. He plans to join the Company May 1st.

Pratt comes to Boston Scientific after 31 years with the Kansas City law firm of Shook, Hardy & Bacon, where he has been a partner and co-chair of the firm's 100-attorney Pharmaceutical and Medical Device Litigation Division. He has a broad range of experience representing a variety of medical device and pharmaceutical companies, and he has received numerous recognitions for his accomplishments.

Pratt has focused his practice on cardiac devices, including pacemakers, defibrillators and cardiac resynchronization therapy devices. He has served as lead outside counsel for Guidant Corporation's Cardiac Rhythm Management business since the early 1990s. Boston Scientific acquired Guidant in 2006.

Prior to joining Shook, Hardy & Bacon, he was a law clerk to Chief Judge Floyd R. Gibson of the U.S. Court of Appeals for the Eighth Circuit.

Pratt is a graduate of Drake University Law School, where he was Editor in Chief of the Law Review.

"As one of the nation's premier medical device attorneys, Tim brings a deep understanding of our industry, as well as long familiarity with our Company," said Tobin. "We are fortunate to have someone of his experience and caliber leading our Legal team and providing strategic advice and counsel on the increasingly intersecting environment of legal and business issues. We look forward to welcoming Tim to Boston Scientific."

Pratt replaces Paul Sandman, who retired as General Counsel in February after 14 years with the Company.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: <http://www.bostonscientific.com/>.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, our medical input process, growth investment and educational publications. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that

actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Paul Donovan, Media Relations, office, +1-508-650-8541, mobile, +1-508-667-5165, Larry Neumann, Investor Relations, +1-508-650-8696, both of Boston Scientific Corporation

Web site: <http://www.bostonscientific.com/>

<https://news.bostonscientific.com/news-releases?item=59046>